Mavenclad (Cladribine Tablets) Data in Multiple Sclerosis Journal Show an Even Greater Treatment Effect in Patients With Highly Active Multiple Sclerosis

Опубликовано Опубликовано в рубрике Универсальное

DARMSTADT, Germany, April 25, 2018 /PRNewswire/ — — Post-hoc analysis from the 2-year CLARITY study demonstrated that Mavenclad reduced the risk of 6-month EDSS progression by 47% vs placebo  — Patients with highly active multiple sclerosis had an even greater treatment effect, reducing the risk by 82% vs placebo Merck, a leading science and technology company, today announced the Multiple […]